<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673554</url>
  </required_header>
  <id_info>
    <org_study_id>GIP and Tachyphylaxis</org_study_id>
    <nct_id>NCT02673554</nct_id>
  </id_info>
  <brief_title>The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP</brief_title>
  <official_title>The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of Glucose-dependent Insulinotropic Polypeptide (GIP) in Patients With Type 2 Diabetes is Not Caused by Rapid Tachyphylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabeteszentrum Bad Lauterberg im Harz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabeteszentrum Bad Lauterberg im Harz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with type 2 diabetes, the incretin hormone glucose-dependent insulinotropic&#xD;
      polypeptide (GIP) has lost its insulinotropic activity, but more so after continuous versus&#xD;
      bolus administration. The design was a two-way crossover design comparing repeated bolus&#xD;
      injection and continuous infusion of GIP under hyperglycaemic clamp conditions. Patients were&#xD;
      age- gender- and weight-matched with type 2 diabetes, first degree relatives of such&#xD;
      patients, and healthy subjects. Investigators performed a:&#xD;
&#xD;
        1. Oral glucose challenge;&#xD;
&#xD;
        2. hyperglycemic clamp (8.5 mmol/l) with two repeated GIP bolus administrations (50 pmol/kg&#xD;
           body weight at 30 and 120 min); and&#xD;
&#xD;
        3. hyperglycemic clamp with continuous administration of GIP (2 pmol.kg-1.min-1 from 30-180&#xD;
           min).&#xD;
&#xD;
      To answer the question, whether rapid tachyphylaxis occurs with regard to the insulinotropic&#xD;
      action of GIP, investigators studied type 2-diabetic patients, their first-degree relatives,&#xD;
      and healthy controls under hyperglycaemic clamp conditions with two GIP bolus injections 90&#xD;
      min apart, and compared this to a continued intravenous infusion of GIP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretory response after GIP bolus or infusion.</measure>
    <time_frame>210 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An oral glucose challenge (75 g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP Bolus</intervention_name>
    <description>bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp</description>
    <arm_group_label>GIP Bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP Clamp</intervention_name>
    <description>hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min</description>
    <arm_group_label>GIP Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral glucose tolerance test (OGTT)</intervention_name>
    <description>an oral glucose challenge (75 g)</description>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperglycemic clamp</intervention_name>
    <description>a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)</description>
    <arm_group_label>GIP Bolus</arm_group_label>
    <arm_group_label>GIP Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Exclusion of pregnancy&#xD;
&#xD;
          -  Exclusion of impaired glucose tolerance or type 2 diabetes in metabolical healthy&#xD;
             subjects&#xD;
&#xD;
          -  current diagnosis of type 2 diabetes according to the guidelines of the German&#xD;
             Diabetes Association (DDG) ( Kerner et al . 2001) in subjects of diabetes group&#xD;
&#xD;
          -  fasting glucose ≤ 150 mg/dl&#xD;
&#xD;
          -  Body-mass-index ≥ 20 kg/m²&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Impaired glucose tolerance or Type 2 diabetes in metabolical healthy subjects&#xD;
&#xD;
          -  Ketone bodies urine diagnostics at least ++&#xD;
&#xD;
          -  Acidosis&#xD;
&#xD;
          -  Fasting blood glucose &gt; 150 mg/dl&#xD;
&#xD;
          -  Body-mass-index &lt; 20 kg/m²&#xD;
&#xD;
          -  No written consent&#xD;
&#xD;
          -  Pregnancy or unsafe contraception in women before menopause&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Angina as current, unsolved clinical problem&#xD;
&#xD;
          -  Inadequately treated or untreated arterial hypertension ( &gt; 160 mmHg systolic and / or&#xD;
             &gt; 95 mmHg diastolic )&#xD;
&#xD;
          -  Infection / fever &gt; 37.5 ° C&#xD;
&#xD;
          -  Treatment with glucocorticoids&#xD;
&#xD;
          -  Insulin therapy within the last three months&#xD;
&#xD;
          -  Anemia with a hemoglobin level &lt; 12 g/dl&#xD;
&#xD;
          -  Liver function limitations&#xD;
&#xD;
          -  Renal impairment ( serum creatinine &gt; 1.5 mg/dl )&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Participation in clinical trials in the last 3 months&#xD;
&#xD;
          -  Inability or unwillingness to comply with the requirements of the Protocol&#xD;
&#xD;
          -  Known hypersensitivity to GIP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Nauck, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabeteszentrum Bad Lauterberg</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabeteszentrum Bad Lauterberg im Harz</investigator_affiliation>
    <investigator_full_name>Michael A. Nauck</investigator_full_name>
    <investigator_title>Prof. Dr. med. Michael A. Nauck</investigator_title>
  </responsible_party>
  <keyword>Glucose-dependent Insulinotropic Polypeptide (GIP)</keyword>
  <keyword>Glucagon-Like Peptide 1 (GLP-1)</keyword>
  <keyword>Incretin</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>Tachyphylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

